Home/Filings/4/0001209191-21-008135
4//SEC Filing

Ingalls Kerry D. 4

Accession 0001209191-21-008135

CIK 0001661460other

Filed

Feb 4, 7:00 PM ET

Accepted

Feb 5, 4:53 PM ET

Size

5.5 KB

Accession

0001209191-21-008135

Insider Transaction Report

Form 4
Period: 2021-02-04
Ingalls Kerry D.
Chief Operating Officer
Transactions
  • Award

    Employee Stock Option (Right to Buy)

    2021-02-04+137,000137,000 total
    Exercise: $9.15Exp: 2031-02-03Common Stock (137,000 underlying)
Footnotes (1)
  • [F1]12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.

Issuer

Poseida Therapeutics, Inc.

CIK 0001661460

Entity typeother

Related Parties

1
  • filerCIK 0001816804

Filing Metadata

Form type
4
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 4:53 PM ET
Size
5.5 KB